For the Inventor, By the Inventor

Enter assignee name

La Chaux-de-Fonds, Switzerland

Ichnos Sciences Sa

USPTO Granted Patents = 13

% Expired Patents = 23.1

CIPO Patents = 3

EPO Patents = 2

Trademarks = 7

Forward Citations = 8

Loading Chart...

Loading Chart...

37 inventors (with patents filed for the assignee):

Samuel Hou (7 out of 12 patents)

Stanislas Blein (5 out of 15 patents)

Rami Lissilaa (5 out of 7 patents)

4. Romain Ollier (5 out of 6 patents)

5. Jonathan Albert Back (4 out of 6 patents)

6. Darko Skegro (4 out of 13 patents)

7. Neelima Khairatkar-Joshi (2 out of 44 patents)

8. Jeremy Loyau (2 out of 5 patents)

9. Antoine Attinger (2 out of 4 patents)

10. Sonia Letestu (2 out of 2 patents)

11. Lionel Duarte (2 out of 2 patents)

12. Filipa Abrantes (2 out of 2 patents)

13. Laure Cahuzac (2 out of 2 patents)

14. Thierry Monney (2 out of 5 patents)

15. Nagarajan Muthukaman (1 out of 8 patents)

13 patents: Sort by Forward Citations

1. 12692314 - CD3/BCMA/CD38 Trispecific Antibodies (2026-07-28),

2. 12351602 - Methods of inactivating viral contaminants (2025-07-08),

3. 12281169 - Antibodies that bind to OX40 and their uses (2025-04-21),

4. 12006367 - CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production (2024-06-11),

5. 11970539 - Antibodies that bind to IL1RAP and uses thereof (2024-04-30),

6. 11891454 - Production of T cell retargeting hetero-dimeric immunoglobulins (2024-02-06),

7. 11884700 - Methods of inactivating viral contaminants (2024-01-30),

8. 11851502 - Production of T cell retargeting hetero-dimeric immunoglobulins (2023-12-26),

9. 11773166 - CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production (2023-10-03),

10. 11407839 - Antibodies that bind to OX40 and their uses (2022-08-09),

11. 10821100 - Triazolone compounds as mPGES-1 inhibitors (2020-11-03),

12. 10758517 - mPGES-1 inhibitor for the treatment of osteoarthritis pain (2020-09-01),

13. 10640564 - Antibodies that bind to CCR6 and their uses (2020-05-05),

Ichnos Sciences SA is a biopharmaceutical company based in La Chaux-de-Fonds, Switzerland, focused on the development of innovative therapies for the treatment of cancer and autoimmune diseases. The organization specializes in the design and advancement of monoclonal antibodies and other biologics, leveraging cutting-edge research to address unmet medical needs. With a commitment to scientific excellence, Ichnos aims to enhance patient outcomes through its robust pipeline of therapeutic candidates.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

13 Patents

#15 in La Chaux-de-Fonds

#878 in Switzerland

#44,988 in the World

La Chaux-de-Fonds, Switzerland

Ichnos Sciences Sa

Forward Citations = 8

37 inventors:

Samuel Hou (7 out of 12 patents)

Stanislas Blein (5 out of 15 patents)

Rami Lissilaa (5 out of 7 patents)

4. Romain Ollier (5 out of 6 patents)

5. Jonathan Albert Back (4 out of 6 patents)

Please report any incorrect information to [email protected]

Loading…